Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2014, Article ID 523584, 6 pages
http://dx.doi.org/10.1155/2014/523584
Clinical Study

The Rate of Decline of Glomerular Filtration Rate May Not Be Associated with Polymorphism of the PPAR 2 Gene in Patients with Type 1 Diabetes and Nephropathy

1Molecular Medicine, Institute of Translational & Stratified Medicine, Plymouth University Schools of Medicine & Dentistry, John Bull Building, Tamar Science Park, Research Way, Plymouth PL6 8BU, UK
2The Influenza Surveillance Section, Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England, London NW9 5EQ, UK

Received 22 August 2013; Revised 12 November 2013; Accepted 13 November 2013; Published 22 January 2014

Academic Editor: Ruth Roberts

Copyright © 2014 Bingmei Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” The American Journal of Physiology—Renal Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  4. T. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” The American Journal of Physiology—Renal Physiology, vol. 277, no. 6, pp. F966–F973, 1999. View at Google Scholar · View at Scopus
  5. M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Google Scholar · View at Scopus
  6. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Shu, B. Wong, G. Zhou et al., “Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 345–349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. A. R. Saltiel and J. M. Olefsky, “Thiazolidinediones in the treatment of insulin resistance and type II diabetes,” Diabetes, vol. 45, no. 12, pp. 1661–1669, 1996. View at Google Scholar · View at Scopus
  10. E. Imano, T. Kanda, Y. Nakatani et al., “Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy,” Diabetes Care, vol. 21, no. 12, pp. 2135–2139, 1998. View at Google Scholar · View at Scopus
  11. A. Werman, A. Hollenberg, G. Solanes, C. Bjørbæk, A. J. Vidal-Puig, and J. S. Flier, “Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). Differential activity of PPARγ1 and -2 isoforms and influence of insulin,” Journal of Biological Chemistry, vol. 272, no. 32, pp. 20230–20235, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Poulsen, G. Andersen, M. Fenger et al., “Impact of two common polymorphisms in the PPARγ gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?” Diabetes, vol. 52, no. 1, pp. 194–198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Altshuler, J. N. Hirschhorn, M. Klannemark et al., “The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes,” Nature Genetics, vol. 26, no. 1, pp. 76–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. S.-M. Herrmann, J. Ringel, J.-G. Wang, J. A. Staessen, and E. Brand, “Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study,” Diabetes, vol. 51, no. 8, pp. 2653–2657, 2002. View at Google Scholar · View at Scopus
  16. M. L. Caramori, L. H. Canani, L. A. Costa, and J. L. Gross, “The human peroxisome proliferators-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabete,” Diabetes, vol. 52, no. 12, pp. 3010–3013, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Zhang, S. Zhu, J. Chen et al., “Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies,” Diabetes Care, vol. 35, no. 6, pp. 1388–1393, 2012. View at Publisher · View at Google Scholar
  18. R. Yu, H. Bo, and S. Huang, “Association between the PPARG gene polymorphism and the risk of diabetic nephropathy: a metal-analysis,” Genetic Testing and Molecular Biomarkers, vol. 16, no. 5, pp. 429–434, 2012. View at Google Scholar
  19. J. Ma, Y. Li, F. Zhou, X. Xu, G. Guo, and Y. Qu, “Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians,” Molecular Vision, vol. 18, pp. 2352–2360, 2012. View at Google Scholar
  20. R. Buzzetti, A. Petrone, A. M. Caiazzo et al., “PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity,” Pediatric Research, vol. 57, no. 1, pp. 138–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Buzzetti, A. Petrone, M. C. Ribaudo et al., “The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity,” European Journal of Human Genetics, vol. 12, no. 12, pp. 1050–1054, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Eftychi, J. M. M. Howson, B. J. Barratt et al., “Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes,” Diabetes, vol. 53, no. 3, pp. 870–873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Jorsal, L. Tarnow, M. Lajer et al., “The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy,” Molecular Genetics and Metabolism, vol. 94, no. 3, pp. 347–351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp. S5–S20, 2003. View at Google Scholar
  25. A. E. Heesom, M. L. Hibberd, A. Millward, and A. G. Demaine, “Polymorphism in the 5′ -end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes,” Diabetes, vol. 46, no. 2, pp. 287–291, 1997. View at Google Scholar · View at Scopus
  26. H. Parving, R. Osterby, and E. Ritz, “Diabetic nephropathy,” in Brenner and Rector’s the Kidney, B. M. Brenner, Ed., vol. 2, chapter 39, pp. 1731–1773, W.B. Saunders Company, Philadelphia, Pa, USA, 6th edition, 2000. View at Google Scholar
  27. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: modification of Diet in Renal Disease Study Group,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar · View at Scopus
  28. S. Andersen, L. Tarnow, F. Cambien et al., “Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?” Diabetes Care, vol. 26, no. 5, pp. 1501–1506, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Andersen, L. Tarnow, F. Cambien et al., “Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?” Kidney International, vol. 62, no. 1, pp. 192–198, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Ek, G. Andersen, S. A. Urhammer et al., “Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant caucasians,” Diabetologia, vol. 44, no. 9, pp. 1170–1176, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Eriksson, V. Lindi, M. Uusitupa et al., “The effects of the pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on insulin sensitivity and insulin metabolism interact with size at birth,” Diabetes, vol. 51, no. 7, pp. 2321–2324, 2002. View at Google Scholar · View at Scopus
  32. Y. Chung-Jen, B. A. Beamer, C. Negri et al., “Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation,” Biochemical and Biophysical Research Communications, vol. 241, no. 2, pp. 270–274, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. F. P. Mancini, O. Vaccaro, L. Sabatino et al., “Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes,” Diabetes, vol. 48, no. 7, pp. 1466–1468, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. B. A. Beamer, C.-J. Yen, R. E. Andersen et al., “Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations,” Diabetes, vol. 47, no. 11, pp. 1806–1808, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Clement, S. Hercberg, B. Passinge et al., “The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes,” International Journal of Obesity and Related Metabolic Disorders, vol. 24, no. 3, pp. 391–393, 2000. View at Google Scholar · View at Scopus
  36. M. Fu, H. Chen, X. Li et al., “Association of Pro12Ala variant in peroxisome proliferator-activated receptor-γ2 gene with type 2 diabetes mellitus,” Chinese Journal of Medical Genetics, vol. 19, no. 3, pp. 234–238, 2002. View at Google Scholar · View at Scopus
  37. K. Hara, T. Okada, K. Tobe et al., “The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes,” Biochemical and Biophysical Research Communications, vol. 271, no. 1, pp. 212–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Meirhaeghe and P. Amouyel, “Impact of genetic variation of PPARγ in humans,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 93–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Meirhaeghe, L. Fajas, N. Helbecque et al., “Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus,” International Journal of Obesity, vol. 24, no. 2, pp. 195–199, 2000. View at Google Scholar · View at Scopus
  40. A. Schäffler, N. Barth, G. Schmitz, B. Zietz, K.-D. Palitzsch, and J. Schölmerich, “Frequency and significance of Pro12ala and Pro115gln polymorphism in gene for peroxisome proliferation-activated receptor-γ2 regarding metabolic parameters in a Caucasian cohort,” Endocrine, vol. 14, no. 3, pp. 369–373, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Mori, H. Ikegami, Y. Kawaguchi et al., “The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes,” Diabetes, vol. 50, no. 4, pp. 891–894, 2001. View at Google Scholar · View at Scopus
  42. J. Ringel, S. Engeli, A. Distler, and A. M. Sharma, “Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus,” Biochemical and Biophysical Research Communications, vol. 254, no. 2, pp. 450–453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Youseff, N. Mohamed, S. Afef et al., “Interaction effects of the Leu162Val PPARα and Pro12Ala PPARγ2 gene varaints with renal function in metabolic syndrome population,” PPAR Research, vol. 2013, Article ID 329862, 10 pages, 2013. View at Publisher · View at Google Scholar